<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00405717</url>
  </required_header>
  <id_info>
    <org_study_id>NH-2006-C002</org_study_id>
    <nct_id>NCT00405717</nct_id>
  </id_info>
  <brief_title>Effects of Atorvastatin Versus Pravastatin on Platelet Inhibition by Clopidogrel</brief_title>
  <official_title>Effects of Atorvastatin Versus Pravastatin on Platelet Inhibition by Clopidogrel in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenyang Northern Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shenyang Northern Hospital</source>
  <brief_summary>
    <textblock>
      Clopidogrel and statins are frequently coadministered in patients with ischemic heart&#xD;
      diseases. Recent reports suggested that clopidogrel's effectiveness in inhibiting adenosine&#xD;
      diphosphate (ADP)-induced platelets aggregation is attenuated by co-administration of certain&#xD;
      statins. The objective of the present study is to define which kind of statins might&#xD;
      interfere with the antiaggregation property of clopidogrel in patients with acute coronary&#xD;
      Syndrome after percutaneous coronary intervention (PCI).&#xD;
&#xD;
      In this prospective randomized study, all patients in test group will receive clopidogrel&#xD;
      plus atorvastatin, and all patients in control group will receive clopidogrel plus&#xD;
      pravastatin. All patients will be followed up for one year. The primary endpoints include&#xD;
      death, non fatal AMI, urgent revascularization. The secondary endpoints include hemorrhage&#xD;
      events and subacute thrombosis events at 1 year.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>major adverse cardiac and cerebral events at 1 year</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>hemorrhage events and subacute thrombosis events at 1 year</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">1300</enrollment>
  <condition>Ischemic Heart Disease</condition>
  <condition>Acute Coronary Syndromes</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atorvastatin,pravastatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with ACS.&#xD;
&#xD;
          -  Between ages of 18 Years and 85 years.&#xD;
&#xD;
          -  Presence of one or several stenosis in native coronary arteries requiring PCI.&#xD;
&#xD;
          -  Willing and able to sign informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A history of bleeding diathesis.&#xD;
&#xD;
          -  New York Heart Association functional class IV.&#xD;
&#xD;
          -  Prior PCI or coronary bypass grafting &lt; 3 months.&#xD;
&#xD;
          -  Contraindications to statins, clopidogrel and aspirin (White blood cells counts &lt;&#xD;
             4Ã—109/L or platelet counts &lt;100 g/l; creatinine clearance &lt;25 ml/ min; active liver&#xD;
             disease).&#xD;
&#xD;
          -  Use of glycoprotein IIb/IIIa inhibitors before PCI.&#xD;
&#xD;
          -  Use of statins before PCI.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yaling Han, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shenyang Northern Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northern Hospital</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2008</verification_date>
  <study_first_submitted>November 28, 2006</study_first_submitted>
  <study_first_submitted_qc>November 29, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2006</study_first_posted>
  <last_update_submitted>November 6, 2008</last_update_submitted>
  <last_update_submitted_qc>November 6, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 7, 2008</last_update_posted>
  <responsible_party>
    <name_title>Yaling Han</name_title>
    <organization>Shenyang Northern Hospital</organization>
  </responsible_party>
  <keyword>ischemic heart disease</keyword>
  <keyword>acute coronary syndromes</keyword>
  <keyword>percutaneous transluminal coronary angioplasty</keyword>
  <keyword>statin</keyword>
  <keyword>clopidogrel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
    <mesh_term>Pravastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

